NASDAQ:INVA Innoviva (INVA) Stock Price, News & Analysis $18.55 +0.36 (+1.98%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$18.28▼$18.7050-Day Range$15.34▼$18.1952-Week Range$12.22▼$18.70Volume500,720 shsAverage Volume613,944 shsMarket Capitalization$1.16 billionP/E Ratio8.36Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Innoviva alerts: Email Address Innoviva MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish18.32% of Float Sold ShortDividend StrengthN/ASustainability-0.33Upright™ Environmental ScoreNews Sentiment0.74Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.16 out of 5 starsMedical Sector803rd out of 936 stocksPharmaceutical Preparations Industry374th out of 436 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Innoviva.Read more about Innoviva's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted18.32% of the float of Innoviva has been sold short.Short Interest Ratio / Days to CoverInnoviva has a short interest ratio ("days to cover") of 20.7, which indicates bearish sentiment.Change versus previous monthShort interest in Innoviva has recently increased by 0.35%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInnoviva does not currently pay a dividend.Dividend GrowthInnoviva does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInnoviva has received a 60.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private equity funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for Innoviva is -0.33. Previous Next 3.7 News and Social Media Coverage News SentimentInnoviva has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Innoviva this week, compared to 1 article on an average week.Search Interest8 people have searched for INVA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows3 people have added Innoviva to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innoviva insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Innoviva is held by insiders.Percentage Held by Institutions99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Innoviva's insider trading history. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Innoviva is 8.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Innoviva is 8.36, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Book Value per Share RatioInnoviva has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Innoviva's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Innoviva Stock (NASDAQ:INVA)Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Read More INVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVA Stock News HeadlinesJuly 25 at 6:28 PM | seekingalpha.comTop 5 Value Stocks For A Big Tech Pullback (SA Quant)July 25 at 5:34 AM | americanbankingnews.comInnoviva (NASDAQ:INVA) Rating Lowered to Buy at StockNews.comJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 17, 2024 | americanbankingnews.comStockNews.com Upgrades Innoviva (NASDAQ:INVA) to Strong-BuyJune 27, 2024 | investorplace.com3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented SurgeJune 21, 2024 | seekingalpha.comInnoviva: Potentially OvervaluedJune 3, 2024 | businesswire.comInnoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 10, 2024 | finance.yahoo.comInnoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed AnalysisJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 10, 2024 | finance.yahoo.comInnoviva First Quarter 2024 Earnings: EPS: US$0.58 (vs US$0.51 in 1Q 2023)May 8, 2024 | investorplace.comINVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | businesswire.comInnoviva to Participate in the BofA Securities Health Care ConferenceApril 24, 2024 | finance.yahoo.comInnoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024April 24, 2024 | businesswire.comInnoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024April 22, 2024 | finance.yahoo.comShould Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?March 8, 2024 | benzinga.comInsider Decision Unfolding At Innoviva: Pavel Raifeld Exercises OptionsMarch 4, 2024 | msn.comArmata enters $35M credit agreement with InnovivaFebruary 29, 2024 | finance.yahoo.comInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressSee More Headlines Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees112Year Founded1996Profitability EPS (Most Recent Fiscal Year)$2.22 Trailing P/E Ratio8.36 Forward P/E Ratio17.02 P/E GrowthN/ANet Income$179.72 million Net Margins58.21% Pretax Margin63.57% Return on Equity28.94% Return on Assets15.39% Debt Debt-to-Equity Ratio0.63 Current Ratio10.42 Quick Ratio9.17 Sales & Book Value Annual Sales$310.46 million Price / Sales3.73 Cash Flow$3.67 per share Price / Cash Flow5.05 Book Value$10.66 per share Price / Book1.74Miscellaneous Outstanding Shares62,440,000Free Float61,571,000Market Cap$1.16 billion OptionableOptionable Beta0.57 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Pavel Raifeld C.F.A. (Age 40)Chief Executive Officer Comp: $754.67kMs. Marianne Zhen CPA (Age 55)Chief Accounting Officer & Secretary Comp: $530.21kMr. Stephen Basso M.B.A. (Age 58)Chief Financial Officer Key CompetitorsArcutis BiotherapeuticsNASDAQ:ARQTOcular TherapeutixNASDAQ:OCULKiniksa PharmaceuticalsNASDAQ:KNSAPhathom PharmaceuticalsNASDAQ:PHATSupernus PharmaceuticalsNASDAQ:SUPNView All CompetitorsInstitutional OwnershipAllspring Global Investments Holdings LLCSold 20,745 shares on 7/26/2024Ownership: 0.146%SummerHaven Investment Management LLCBought 980 shares on 7/24/2024Ownership: 0.096%EdgeRock Capital LLCBought 1,910 shares on 7/24/2024Ownership: 0.003%Hennion & Walsh Asset Management Inc.Bought 10,175 shares on 7/20/2024Ownership: 0.016%QRG Capital Management Inc.Bought 12,512 shares on 7/12/2024Ownership: 0.122%View All Institutional Transactions INVA Stock Analysis - Frequently Asked Questions How have INVA shares performed this year? Innoviva's stock was trading at $16.04 at the beginning of the year. Since then, INVA shares have increased by 15.6% and is now trading at $18.55. View the best growth stocks for 2024 here. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) posted its earnings results on Wednesday, May, 8th. The biotechnology company reported $0.46 earnings per share for the quarter. The biotechnology company had revenue of $77.50 million for the quarter. Innoviva had a trailing twelve-month return on equity of 28.94% and a net margin of 58.21%. Who are Innoviva's major shareholders? Innoviva's top institutional shareholders include Harbor Capital Advisors Inc. (0.15%), Allspring Global Investments Holdings LLC (0.15%), SG Americas Securities LLC (0.13%) and QRG Capital Management Inc. (0.12%). Insiders that own company stock include Marianne Zhen, Pavel Raifeld and Innoviva, Inc. View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX). This page (NASDAQ:INVA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
